GLOBAL STUDIES
We work alongside medical experts, professionals and world leaders in the field to provide extensive research, clinical studies and testing.
Independent observational studies have demonstrated the safety and effectiveness of the Paxman Scalp Cooling System in the prevention of chemotherapy induced hair loss with widely used chemotherapy dosages and regimens.
All trials have reported high levels of patient comfort and acceptability, with low numbers of patients discontinuing scalp cooling. Our clinical efficacy brochure details the proven performance in five different studies carried out using the Paxman Scalp Cooling System.
United Kingdom Study
UK observational study reports an 89% success rate following use of the Paxman cold cap system in breast cancer patients,
with only 11% with severe hair loss requiring wigs.
Norway Study
Norwegian observational study reports a 92% success rate following use of the Paxman cold cap system in 54 breast cancer patients treated with FEC/FAC or paclitaxel.
Netherlands Study 1
Observational study reports a 40% reduction of head covers when using the Paxman cold cap system in breast cancer patients.
Netherlands Study 2
88% of patients didn’t require a head cover or wig following 45 minutes post-infusion cooling after 3 weekly docetaxel.
Netherlands Study 3
48% success rate in patients treated with different cancer types.
Swiss Study
93.7% patient assessment of scalp cooling was above reasonably well.
